The USFDA has issued a warning letter to Vista Pharmaceutical Ltd for ‘violation’ of Current Good Manufacturing Practices at its plant in Gopalapally, Nalgonda district. According to the letter issued about a week ago, it found ‘significant’ violations in the inspection it conducted last year. The facility makes finished dosages/pharmaceuticals. The company’s scrip fell 4.93 per cent on the BSE on Wednesday to end at ₹32.75.
Published on July 12, 2017
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.